RxDoctor Payments Data

Thelinh Nguyen, MD

Vascular Surgery · Reno, NVNPI 1720031982

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.3% of the total across 205 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Medtronic at 49.5% of the total.

$16,223in general payments, 2019–2025

Across 205 payments — averaging $79.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$8K
  • Shockwave Medical, Inc$3K
  • W. L. Gore & Associates, Inc.$2K
  • Lemaitre Vascular, Inc.$693
  • Cook Medical LLC$468
  • Boston Scientific$411
  • plus $2K from 16 others

What the payments were for

  • Speaking & faculty fees$450%
  • Travel & lodging$7164%
  • Food & beverage$15,46295%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,223 in reported general payments places this provider in the 70th percentile of 28 vascular surgery providers in Nevada.

See all vascular surgery providers in Nevada

Medicare billing

Part B allowed, 2024
$140,251
Medicare patients
231
Services billed
536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate41$518
Cilostazol24$362
Simvastatin13$77
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen14$33

Paid to pharmacies, not to this prescriber.

Other vascular surgery in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →